MD Anderson, Eisbach Bio Announce Strategic Collaboration to Develop Medicines Targeting Epigenetic Machinery in Oncology
January 19, 2022
January 19, 2022
HOUSTON, Texas, Jan. 19 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Jan. 18, 2022:
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.
The agreement aligns the drug discovery and development expertise of MD Anderson&# . . .
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover and develop precision oncology drugs that target synthetic lethal engines key to tumor genome evolution.
The agreement aligns the drug discovery and development expertise of MD Anderson&# . . .